Biosynth, a developer and supplier of critical raw materials and services for life sciences and diagnostics, has opened an expanded GMP bioconjugation facility at its existing Berlin site.

This strategic expansion significantly enhances Biosynth’s specialized manufacturing capabilities in conjugate vaccines and conjugate drugs, activated PEGs, and polymer-based drug delivery excipients as part of its global manufacturing network.

Thomas Eisele, COO, stated, “We are thrilled to officially open the new expansion to our bioconjugation facility in Berlin, which represents a significant enhancement to our existing operations. This suite enables the scalable, diverse, high-quality conjugation services that our customers need to advance to the next generation of therapies.”

Frank Leenders, General Manager for the Berlin site, added, “The construction of our new facility, including class D and C cleanrooms, represents a natural evolution of our Berlin operation—in many ways, we are growing alongside our customers. The additional refurbishment of our existing facility enhances our GMP manufacturing capabilities, reinforcing our commitment to meeting the evolving needs of our customers.”

Being able to support projects fully from initial bioconjugate process development to commercial GMP supply enables Biosynth to provide specialized conjugation solutions for diagnostics and therapeutics, strengthening the company’s position as a trusted partner in the Life Science industry.